Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa; P. M. Duong, Connie; Tidjani Alou, Maryam; Daillère, Romain; Fluckiger, Aurélie; Messaoudene, Meriem; Rauber, Conrad; P. Roberti, Maria; Fidelle, Marine; Flament, Caroline; Poirier-Colame, Vichnou; Opolon, Paule; Klein, Christophe; Iribarren, Kristina; Mondragón, Laura; Jacquelot, Nicolas; Qu, Bo; Ferrere, Gladys; Clémenson, Céline; Mezquita, Laura; Remon Masip, Jordi; Naltet, Charles; Brosseau, Solenn; Kaderbhai, Coureche; Richard, Corentin; Rizvi, Hira; Levenez, Florence; Galleron, Nathalie; Quinquis, Benoit; Pons, Nicolas; Ryffel, Bernhard; Minard-Colin, Véronique; Gonin, Patrick; Soria, Jean-Charles; Deutsch, Eric; Loriot, Yohann; Ghiringhelli, François; Zalcman, Gérard; Goldwasser, François; Escudier, Bernard; D. Hellmann, Matthew; Eggermont, Alexander; Raoult, Didier; Albiges, Laurence; Kroemer, Guido; Zitvogel, Laurence

doi:10.1126/science.aan3706

Public

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Shared by NobleBlocks on Jan 5, 2018 • 12:00 AM UTC

Authors:

Bertrand Routy

Emmanuelle Le Chatelier

Lisa Derosa

Abstract

Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung ...

Discussions